Sphingolipid metabolism and drug resistance in hematological malignancies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 891-903

  Gouazé Andersson, Valérie ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Ceramide; Drug resistance; Glucosylceramide; Glucosylceramide synthase; Glycosphingolipids; Leukemia; P glycoprotein; Sphingolipids

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABC TRANSPORTER; CERAMIDASE; CERAMIDE; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DIPHTHERIA TOXIN 388 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION PROTEIN; ELACRIDAR; FENRETINIDE; FLUDARABINE; GLYCOLIPID; GLYCOPROTEIN P; GLYCOSPHINGOLIPID; HAPLOPHYTIN A; JUGLONE; LAMELLARIN D; MITOXANTRONE; PACLITAXEL; SPHINGOLIPID; TAMOXIFEN; THREO 1 PHENYL 2 DECANOYLAMINO 3 MORPHOLINO 1 PROPANOL; THREO 1 PHENYL 2 HEXADECANOYLAMINO 3 MORPHOLINO 1 PROPANOL; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALSPODAR; VINBLASTINE; VINCRISTINE;

APOPTOSIS; CANCER CELL CULTURE; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIPID METABOLISM; LIPOGENESIS; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW;

EID: 80054072695     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655069     Document Type: Review

References (183)

1. Ruvolo, P. P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res., 2003, 47 (5), 383-92.
2. Zheng, W.; Kollmeyer, J.; Symolon, H.; Momin, A.; Munter, E.; Wang, E.; Kelly, S.; Allegood, J. C.; Liu, Y.; Peng, Q.; Ramaraju, H.; Sullards, M. C.; Cabot, M.; Merrill, A. H., Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta, 2006, 1758 (12), 1864-1884.
3. Ryland, L. K.; Fox, T. E.; Liu, X.; Loughran, T. P.; Kester, M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol. Ther., 2011, 11 (2), 138-149.
4. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Ichikawa, S.; Hirabayashi, Y.; Cabot, M. C. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp. Cell Res., 1999, 252 (2), 464-470.
5. Bleicher, R. J.; Cabot, M. C. Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta, 2002, 1585 (2-3), 172-178.
6. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem., 1999, 274 (2), 1140-1146.
7. Meng, A.; Luberto, C.; Meier, P.; Bai, A.; Yang, X.; Hannun, Y. A.; Zhou, D. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp. Cell Res., 2004, 292 (2), 385-392.
8. Gomez-Munoz, A.; Gangoiti, P.; Granado, M. H.; Arana, L.; Ouro, A. Ceramide-1-phosphate in cell survival and inflammatory signaling. Adv. Exp. Med. Biol., 2010, 688, 118-130.
9. Jarvis, W. D.; Fornari, F. A., Jr.; Auer, K. L.; Freemerman, A. J.; Szabo, E.; Birrer, M. J.; Johnson, C. R.; Barbour, S. E.; Dent, P.; Grant, S. Coordinate regulation of stress-and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol. Pharmacol., 1997, 52 (6), 935-947.
10. Klostergaard, J.; Auzenne, E.; Leroux, E. Characterization of cytotoxicity induced by sphingolipids in multidrug-resistant leukemia cells. Leuk Res, 1998, 22 (11), 1049-56.
11. Wang, H.; Maurer, B. J.; Liu, Y. Y.; Wang, E.; Allegood, J. C.; Kelly, S.; Symolon, H.; Liu, Y.; Merrill, A. H., Jr.; Gouaze-Andersson, V.; Yu, J. Y.; Giuliano, A. E.; Cabot, M. C. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol. Cancer Ther., 2008, 7 (9), 2967-2976.
12. Pitson, S. M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci., 2011, 36 (2), 97-107.
13. Jendiroba, D. B.; Klostergaard, J.; Keyhani, A.; Pagliaro, L.; Freireich, E. J. Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-Ndimethylsphingosine. Leuk. Res., 2002, 26 (3), 301-310.
14. Ekiz, H. A.; Baran, Y. Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int. J. Cancer, 2010, 127 (7), 1497-1506.
15. Ricci, C.; Onida, F.; Ghidoni, R. Sphingolipid players in the leukemia arena. Biochim. Biophys. Acta, 2006, 1758 (12), 2121-2132.
16. Leist, M.; Jaattela, M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol., 2001, 2 (8), 589-598.
17. Liu, J.; Mathias, S.; Yang, Z.; Kolesnick, R. N. Renaturation and tumor necrosis factor-alpha stimulation of a 97-kDa ceramideactivated protein kinase. J. Biol. Chem., 1994, 269 (4), 3047-3052.
18. Karasavvas, N.; Erukulla, R. K.; Bittman, R.; Lockshin, R.; Zakeri, Z. Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis. Eur. J. Biochem., 1996, 236 (2), 729-37
19. Wolff, R. A.; Dobrowsky, R. T.; Bielawska, A.; Obeid, L. M.; Hannun, Y. A. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem., 1994, 269 (30), 19605-19609.
20. Yao, B.; Zhang, Y.; Delikat, S.; Mathias, S.; Basu, S.; Kolesnick, R. Phosphorylation of Raf by ceramide-activated protein kinase. Nature, 1995, 378 (6554), 307-310.
21. Malisan, F.; Testi, R. Lipid signaling in CD95-mediated apoptosis. FEBS Lett., 1999, 452 (1-2), 100-103.
22. Brenner, B.; Koppenhoefer, U.; Weinstock, C.; Linderkamp, O.; Lang, F.; Gulbins, E. Fas-or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. Biol. Chem., 1997, 272 (35), 22173-22181.
23. Testi, R. Sphingomyelin breakdown and cell fate. Trends Biochem. Sci., 1996, 21 (12), 468-471.
24. Bieberich, E.; Kawaguchi, T.; Yu, R. K. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J. Biol. Chem., 2000, 275 (1), 177-181.
25. Basu, S.; Bayoumy, S.; Zhang, Y.; Lozano, J.; Kolesnick, R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J. Biol. Chem., 1998, 273 (46), 30419-30426.
26. Bezombes, C.; Plo, I.; Mansat-De Mas, V.; Quillet-Mary, A.; Negre-Salvayre, A.; Laurent, G.; Jaffrezou, J. P. Oxidative stressinduced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C. Faseb J., 2001, 15 (9), 1583-1585.
27. Sawai, H.; Okazaki, T.; Yamamoto, H.; Okano, H.; Takeda, Y.; Tashima, M.; Sawada, H.; Okuma, M.; Ishikura, H.; Umehara, H.; et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J. Biol. Chem., 1995, 270 (45), 27326-27331.
28. Verheij, M.; Bose, R.; Lin, X. H.; Yao, B.; Jarvis, W. D.; Grant, S.; Birrer, M. J.; Szabo, E.; Zon, L. I.; Kyriakis, J. M.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature, 1996, 380 (6569), 75-79.
29. Enomoto, A.; Suzuki, N.; Hirano, K.; Matsumoto, Y.; Morita, A.; Sakai, K.; Koyama, H. Involvement of SAPK/JNK pathway in Xray-induced rapid cell death of human T-cell leukemia cell line MOLT-4. Cancer Lett., 2000, 155 (2), 137-144.
30. Ji, L.; Zhang, G.; Hirabayashi, Y. Inhibition of tumor necrosis factor alpha-and ceramide-induced internucleosomal DNA fragmentation by herbimycin A in U937 cells. Biochem. Biophys. Res. Commun., 1995, 212 (2), 640-647.
31. Obeid, L. M.; Linardic, C. M.; Karolak, L. A.; Hannun, Y. A. Programmed cell death induced by ceramide. Science, 1993, 259 (5102), 1769-1771.
32. Zhang, P.; Liu, B.; Kang, S. W.; Seo, M. S.; Rhee, S. G.; Obeid, L. M. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J. Biol. Chem., 1997, 272 (49), 30615-30618.
33. Nardini, M.; Leonardi, F.; Scaccini, C.; Virgili, F. Modulation of ceramide-induced NF-kappaB binding activity and apoptotic response by caffeic acid in U937 cells: comparison with other antioxidants. Free Radic. Biol. Med., 2001, 30 (7), 722-733.
34. Zhang, P.; Liu, B.; Jenkins, G. M.; Hannun, Y. A.; Obeid, L. M. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J. Biol. Chem., 1997, 272 (15), 9609-9612.
35. Quillet-Mary, A.; Mansat, V.; Duchayne, E.; Come, M. G.; Allouche, M.; Bailly, J. D.; Bordier, C.; Laurent, G. Daunorubicininduced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia, 1996, 10 (3), 417-425.
36. Jaffrezou, J. P.; Levade, T.; Bettaieb, A.; Andrieu, N.; Bezombes, C.; Maestre, N.; Vermeersch, S.; Rousse, A.; Laurent, G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. Embo. J., 1996, 15 (10), 2417-2424.
37. Mansat, V.; Laurent, G.; Levade, T.; Bettaieb, A.; Jaffrezou, J. P. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res., 1997, 57 (23), 5300-5304.
38. Mansat, V.; Bettaieb, A.; Levade, T.; Laurent, G.; Jaffrezou, J. P. Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Faseb J., 1997, 11 (8), 695-702.
39. Furlong, S. J.; Ridgway, N. D.; Hoskin, D. W. Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int. J. Oncol., 2008, 32 (3), 537-544.
40. Murate, T.; Suzuki, M.; Hattori, M.; Takagi, A.; Kojima, T.; Tanizawa, T.; Asano, H.; Hotta, T.; Saito, H.; Yoshida, S.; Tamiya-Koizumi, K. Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem., 2002, 277 (12), 9936-9943.
41. Dbaibo, G. S.; Kfoury, Y.; Darwiche, N.; Panjarian, S.; Kozhaya, L.; Nasr, R.; Abdallah, M.; Hermine, O.; El-Sabban, M.; de The, H.; Bazarbachi, A. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica, 2007, 92 (6), 753-762.
42. Nica, A. F.; Tsao, C. C.; Watt, J. C.; Jiffar, T.; Kurinna, S.; Jurasz, P.; Konopleva, M.; Andreeff, M.; Radomski, M. W.; Ruvolo, P. P. Ceramide promotes apoptosis in chronic myelogenous leukemiaderived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle, 2008, 7 (21), 3362-3370.
43. Chapman, J. V.; Gouaze-Andersson, V.; Messner, M. C.; Flowers, M.; Karimi, R.; Kester, M.; Barth, B. M.; Liu, X.; Liu, Y. Y.; Giuliano, A. E.; Cabot, M. C. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochem. Pharmacol., 2010, 80 (3), 308-315.
44. Callaghan, R.; Higgins, C. F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer, 1995, 71 (2), 294-299.
45. Eckford, P. D.; Sharom, F. J. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J., 2005, 389 (Pt 2), 517-526.
46. Borst, P.; Zelcer, N.; van Helvoort, A. ABC transporters in lipid transport. Biochim. Biophys. Acta, 2000, 1486 (1), 128-144.
47. van Helvoort, A.; Smith, A. J.; Sprong, H.; Fritzsche, I.; Schinkel, A. H.; Borst, P.; van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, 1996, 87 (3), 507-517.
48. De Rosa, M. F.; Sillence, D.; Ackerley, C.; Lingwood, C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem., 2004, 279 (9), 7867-7876.
49. Ho, S. Y.; Chen, W. C.; Chiu, H. W.; Lai, C. S.; Guo, H. R.; Wang, Y. J. Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation. Chem. Biol. Interact., 2009, 179 (2-3), 304-313.
50. Moon, D. O.; Kim, M. O.; Lee, J. D.; Choi, Y. H.; Kim, G. Y. Rosmarinic acid sensitizes cell death through suppression of TNFalpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells. Cancer Lett., 2010, 288 (2), 183-191.
51. Goto, H.; Takahashi, H.; Fujii, H.; Ikuta, K.; Yokota, S. N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int. J. Hematol., 2003, 78 (3), 219-225.
52. Kim, B. M.; Choi, Y. J.; Lee, Y. H.; Joe, Y. A.; Hong, S. H. N, NDimethyl phytosphingosine sensitizes HL-60/MX2, a multidrugresistant variant of HL-60 cells, to doxorubicin-induced cytotoxicity through ROS-mediated release of cytochrome c and AIF. Apoptosis, 2010, 15 (8), 982-993
53. Kowaltowski, A. J.; Fenton, R. G.; Fiskum, G. Bcl-2 family proteins regulate mitochondrial reactive oxygen production and protect against oxidative stress. Free Radic. Biol. Med., 2004, 37 (11), 1845-1853.
54. Kryston, T. B.; Georgiev, A. B.; Pissis, P.; Georgakilas, A. G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res., 2011, 711 (1-2), 193-201.
55. Mates, J. M.; Perez-Gomez, C.; Nunez de Castro, I. Antioxidant enzymes and human diseases. Clin. Biochem., 1999, 32 (8), 595-603.
56. Batinic-Haberle, I.; Reboucas, J. S.; Spasojevic, I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid. Redox. Signal., 2011, 13 (6), 877-918.
57. Rosato, R. R.; Maggio, S. C.; Almenara, J. A.; Payne, S. G.; Atadja, P.; Spiegel, S.; Dent, P.; Grant, S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol., 2006, 69 (1), 216-225.
58. Maurer, B. J.; Melton, L.; Billups, C.; Cabot, M. C.; Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst., 2000, 92 (23), 1897-1909.
59. Delia, D.; Aiello, A.; Lombardi, L.; Pelicci, P. G.; Grignani, F.; Formelli, F.; Menard, S.; Costa, A.; Veronesi, U.; et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res., 1993, 53 (24), 6036-6041.
60. O'Donnell, P. H.; Guo, W. X.; Reynolds, C. P.; Maurer, B. J. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia, 2002, 16 (5), 902-910.
61. Kang, M. H.; Wan, Z.; Kang, Y. H.; Sposto, R.; Reynolds, C. P. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J. Natl. Cancer Inst., 2008, 100 (8), 580-595.
62. Morales, M. C.; Perez-Yarza, G.; Rementeria, N. N.; Boyano, M. D.; Apraiz, A.; Gomez-Munoz, A.; Perez-Andres, E.; Asumendi, A. 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2. Free Radic. Res., 2007, 41 (5), 591-601.
63. Darwiche, N.; Abou-Lteif, G.; Bazarbachi, A. Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax. Leukemia, 2007, 21 (2), 261-269.
64. Lai, W. L.; Wong, N. S. The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp. Cell Res., 2008, 314 (8), 1667-1682.
65. Jiang, L.; Pan, X.; Chen, Y.; Wang, K.; Du, Y.; Zhang, J. Preferential involvement of both ROS and ceramide in fenretinide-induced apoptosis of HL60 rather than NB4 and U937 cells. Biochem. Biophys. Res. Commun., 2011, 405 (2), 314-318.
66. Maurer, B. J.; Kalous, O.; Yesair, D. W.; Wu, X.; Janeba, J.; Maldonado, V.; Khankaldyyan, V.; Frgala, T.; Sun, B. C.; McKee, R. T.; Burgess, S. W.; Shaw, W. A.; Reynolds, C. P. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-XSORB organized lipid complex. Clin. Cancer. Res., 2007, 13 (10), 3079-3086.
67. Pastorino, J. G.; Tafani, M.; Rothman, R. J.; Marcinkeviciute, A.; Hoek, J. B.; Farber, J. L.; Marcineviciute, A. Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore. J. Biol. Chem., 1999, 274 (44), 31734-31739
68. De Maria, R.; Lenti, L.; Malisan, F.; d'Agostino, F.; Tomassini, B.; Zeuner, A.; Rippo, M. R.; Testi, R. Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science, 1997, 277 (5332), 1652-1655
69. Quillet-Mary, A.; Jaffrezou, J. P.; Mansat, V.; Bordier, C.; Naval, J.; Laurent, G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem., 1997, 272 (34), 21388-21395
70. Gudz, T. I.; Tserng, K. Y.; Hoppel, C. L. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J. Biol. Chem., 1997, 272 (39), 24154-24158.
71. Cuvillier, O.; Levade, T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood, 2001, 98 (9), 2828-2836.
72. Won, K. J.; Chung, K. S.; Lee, Y. S.; Alia, M. S.; Pervez, M. K.; Fatima, S.; Choi, J. H.; Lee, K. T. Haplophytin-A induces caspase-8-mediated apoptosis via the formation of death-inducing signaling complex in human promyelocytic leukemia HL-60 cells. Chem. Biol. Interact., 2010, 188 (3), 505-511.
73. Xu, H. L.; Yu, X. F.; Qu, S. C.; Zhang, R.; Qu, X. R.; Chen, Y. P.; Ma, X. Y.; Sui, D. Y. Anti-proliferative effect of Juglone from Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing apoptosis through the mitochondria-dependent pathway. Eur. J. Pharmacol., 2010, 645 (1-3), 14-22.
74. Cuvillier, O.; Edsall, L.; Spiegel, S. Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells. J. Biol. Chem., 2000, 275 (21), 15691-15700.
75. Hannun, Y. A.; Luberto, C. Ceramide in the eukaryotic stress response. Trends Cell Biol., 2000, 10 (2), 73-80.
76. Tepper, A. D.; Cock, J. G.; de Vries, E.; Borst, J.; van Blitterswijk, W. J. CD95/Fas-induced ceramide formation proceeds with slow kinetics and is not blocked by caspase-3/CPP32 inhibition. J. Biol. Chem., 1997, 272 (39), 24308-24312.
77. Tepper, A. D.; de Vries, E.; van Blitterswijk, W. J.; Borst, J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95-and DNA damage-induced apoptosis. J. Clin. Invest., 1999, 103 (7), 971-978.
78. Kim, H. J.; Mun, J. Y.; Chun, Y. J.; Choi, K. H.; Kim, M. Y. Baxdependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett., 2001, 505 (2), 264-268.
79. Rodriguez-Lafrasse, C.; Alphonse, G.; Broquet, P.; Aloy, M. T.; Louisot, P.; Rousson, R. Temporal relationships between ceramide production, caspase activation and mitochondrial dysfunction in cell lines with varying sensitivity to anti-Fas-induced apoptosis. Biochem J., 2001, 357 (Pt 2), 407-416.
80. Morales, J. C.; Ruiz-Magana, M. J.; Carranza, D.; Ortiz-Ferron, G.; Ruiz-Ruiz, C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett., 2010, 297 (1), 91-100.
81. Ballot, C.; Kluza, J.; Martoriati, A.; Nyman, U.; Formstecher, P.; Joseph, B.; Bailly, C.; Marchetti, P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol. Cancer Ther., 2009, 8 (12), 3307-3317.
82. Zhang, J.; Alter, N.; Reed, J. C.; Borner, C.; Obeid, L. M.; Hannun, Y. A. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acad. Sci. U.S.A., 1996, 93 (11), 5325-5328.
83. Quintans, J.; Kilkus, J.; McShan, C. L.; Gottschalk, A. R.; Dawson, G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem. Biophys. Res. Commun., 1994, 202 (2), 710-714.
84. Bettaieb, A.; Plo, I.; Mansat-De Mas, V.; Quillet-Mary, A.; Levade, T.; Laurent, G.; Jaffrezou, J. P. Daunorubicin-and mitoxantronetriggered phosphatidylcholine hydrolysis: implication in druginduced ceramide generation and apoptosis. Mol. Pharmacol., 1999, 55 (1), 118-125.
85. Biswal, S. S.; Datta, K.; Acquaah-Mensah, G. K.; Kehrer, J. P. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology, 2000, 154 (1-3), 45-53.
86. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R. Ceramide synthase mediates daunorubicininduced apoptosis: an alternative mechanism for generating death signals. Cell, 1995, 82 (3), 405-414.
87. Turnbull, K. J.; Brown, B. L.; Dobson, P. R. Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells. Leukemia, 1999, 13 (7), 1056-1061.
88. Myrick, D.; Blackinton, D.; Klostergaard, J.; Kouttab, N.; Maizel, A.; Wanebo, H.; Mehta, S. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk. Res., 1999, 23 (6), 569-578.
89. Okazaki, T.; Bell, R. M.; Hannun, Y. A. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem., 1989, 264 (32), 19076-19080.
90. Carlson, R. W.; O'Neill, A. M.; Goldstein, L. J.; Sikic, B. I.; Abramson, N.; Stewart, J. A.; Davidson, N. E.; Wood, W. C. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest., 2006, 24 (7), 677-681.
91. Lacayo, N. J.; Duran, G. E.; Sikic, B. I. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrugresistant cells. J. Exp. Ther. Oncol., 2003, 3 (3), 127-135.
92. Azare, J.; Pankova-Kholmyansky, I.; Salnikow, K.; Cohen, D.; Flescher, E. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of Pglycoprotein. Oncol. Res., 2000, 12 (8), 315-323.
93. Cabot, M. C.; Han, T. Y.; Giuliano, A. E. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett., 1998, 431 (2), 185-188.
94. Goulding, C. W.; Giuliano, A. E.; Cabot, M. C. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett., 2000, 149 (1-2), 143-151.
95. Senchenkov, A.; Han, T. Y.; Wang, H.; Frankel, A. E.; Kottke, T. J.; Kaufmann, S. H.; Cabot, M. C. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GMCSF), a truncated diphtheria toxin fused to human GM-CSF. Blood, 2001, 98 (6), 1927-1934.
96. Frankel, A. E.; Hall, P. D.; McLain, C.; Safa, A. R.; Tagge, E. P.; Kreitman, R. J. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug. Chem., 1998, 9 (4), 490-496.
97. Hogge, D. E.; Willman, C. L.; Kreitman, R. J.; Berger, M.; Hall, P. D.; Kopecky, K. J.; McLain, C.; Tagge, E. P.; Eaves, C. J.; Frankel, A. E. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocytemacrophage colony-stimulating factor fusion protein. Blood, 1998, 92 (2), 589-595.
98. Frankel, A. E.; Lilly, M.; Kreitman, R.; Hogge, D.; Beran, M.; Freedman, M. H.; Emanuel, P. D.; McLain, C.; Hall, P.; Tagge, E.; Berger, M.; Eaves, C. Diphtheria toxin fused to granulocytemacrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood, 1998, 92 (11), 4279-4286.
99. Frankel, A. E.; Powell, B. L.; Hall, P. D.; Case, L. D.; Kreitman, R. J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin. Cancer Res., 2002, 8 (5), 1004-1013.
100. Westcott, M. M.; Abi-Habib, R. J.; Cohen, K. A.; Willingham, M. C.; Liu, S.; Bugge, T. H.; Leppla, S. H.; Frankel, A. E. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factorinduced hepatotoxicity is mediated by Kupffer cells. Mol. Cancer Ther., 2004, 3 (12), 1681-1689.
101. Hall, P. D.; Sinha, D.; Frankel, A. E. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunol. Immunother., 2006, 55 (8), 928-932.
102. Mengubas, K.; Riordan, F. A.; Bravery, C. A.; Lewin, J.; Owens, D. L.; Mehta, A. B.; Hoffbrand, A. V.; Wickremasinghe, R. G. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism. Oncogene, 1999, 18 (15), 2499-2506.
103. Perry, D. K.; Carton, J.; Shah, A. K.; Meredith, F.; Uhlinger, D. J.; Hannun, Y. A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem., 2000, 275 (12), 9078-9084.
104. Laethem, R. M.; Hannun, Y. A.; Jayadev, S.; Sexton, C. J.; Strum, J. C.; Sundseth, R.; Smith, G. K. Increases in neutral, Mg2+-dependent and acidic, Mg2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843. Blood, 1998, 91 (11), 4350-4360.
105. Liani, E.; Rothem, L.; Bunni, M. A.; Smith, C. A.; Jansen, G.; Assaraf, Y. G. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylationdependent novel antifolates in multiple human leukemia sublines. Int. J. Cancer, 2003, 103 (5), 587-599.
106. Wielinga, P.; Hooijberg, J. H.; Gunnarsdottir, S.; Kathmann, I.; Reid, G.; Zelcer, N.; van der Born, K.; de Haas, M.; van der Heijden, I.; Kaspers, G.; Wijnholds, J.; Jansen, G.; Peters, G.; Borst, P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res., 2005, 65 (10), 4425-4430.
107. Funato, T.; Harigae, H.; Abe, S.; Sasaki, T. Assessment of drug resistance in acute myeloid leukemia. Expert Rev. Mol. Diagn., 2004, 4 (5), 705-713.
108. Basara, N.; Radosevic-Radojkovic, N.; Colovic, M.; Boskovic, D.; Rolovic, Z. In vitro drug sensitivity of leukemic progenitors and Pglycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Eur. J. Haematol., 1995, 55 (2), 83-87.
109. Campos, L.; Guyotat, D.; Archimbaud, E.; Calmard-Oriol, P.; Tsuruo, T.; Troncy, J.; Treille, D.; Fiere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 1992, 79 (2), 473-476.
110. Damiani, D.; Michieli, M.; Ermacora, A.; Candoni, A.; Raspadori, D.; Geromin, A.; Stocchi, R.; Grimaz, S.; Masolini, P.; Michelutti, A.; Scheper, R. J.; Baccarani, M. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica, 1998, 83 (4), 290-297.
111. Del Poeta, G.; Stasi, R.; Aronica, G.; Venditti, A.; Cox, M. C.; Bruno, A.; Buccisano, F.; Masi, M.; Tribalto, M.; Amadori, S.; Papa, G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 1996, 87 (5), 1997-2004.
112. Wood, P.; Burgess, R.; MacGregor, A.; Yin, J. A. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br. J. Haematol., 1994, 87 (3), 509-514.
113. Nussler, V.; Pelka-Fleischer, R.; Zwierzina, H.; Nerl, C.; Beckert, B.; Gieseler, F.; Diem, H.; Ledderose, G.; Gullis, E.; Sauer, H.; Wilmanns, W. P-glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia, 1996, 10 Suppl 3, S23-S31.
114. Hunault, M.; Zhou, D.; Delmer, A.; Ramond, S.; Viguie, F.; Cadiou, M.; Perrot, J. Y.; Levy, V.; Rio, B.; Cymbalista, F.; Zittoun, R.; Marie, J. P. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol., 1997, 74 (2), 65-71.
115. van den Heuvel-Eibrink, MM.; van der Holt, B.; te Boekhorst, PA.; Pieters, R.; Schoester, M.; Lowenberg, B.; Sonneveld, P. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br. J. Haematol., 1997, 99 (1), 76-83.
116. Pallis, M.; Turzanski, J.; Harrison, G.; Wheatley, K.; Langabeer, S.; Burnett, A. K.; Russell, N. H. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br. J. Haematol., 1999, 104 (2), 307-312.
117. Abd El-Ghaffar, H. A.; Aladle, D. A.; Farahat, S. E.; Abd El-Hady, N. P-glycoprotein (P-170) expression in acute leukemias. Hematology, 2006, 11 (1), 35-41.
118. Prenkert, M.; Uggla, B.; Tina, E.; Tidefelt, U.; Strid, H. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res., 2009, 29 (10), 4071-4076.
119. Suvannasankha, A.; Minderman, H.; O'Loughlin, K. L.; Nakanishi, T.; Ford, L. A.; Greco, W. R.; Wetzler, M.; Ross, D. D.; Baer, M. R. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br. J. Haematol., 2004, 127 (4), 392-398.
120. Ho, M. M.; Hogge, D. E.; Ling, V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp. Hematol., 2008, 36 (4), 433-442.
121. van den Heuvel-Eibrink, MM.; Wiemer, EA.; Prins, A.; Meijerink, JP.; Vossebeld, PJ.; van der Holt, B.; Pieters, R.; Sonneveld, P. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia, 2002, 16 (5), 833-839.
122. Pallis, M.; Turzanski, J.; Higashi, Y.; Russell, N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk. Lymphoma, 2002, 43 (6), 1221-1228.
123. O'Brien, M. M.; Lacayo, N. J.; Lum, B. L.; Kshirsagar, S.; Buck, S.; Ravindranath, Y.; Bernstein, M.; Weinstein, H.; Chang, M. N.; Arceci, R. J.; Sikic, B. I.; Dahl, G. V. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr. Blood Cancer, 2010, 54 (5), 694-702.
124. Kolitz, J. E.; George, S. L.; Marcucci, G.; Vij, R.; Powell, B. L.; Allen, S. L.; DeAngelo, D. J.; Shea, T. C.; Stock, W.; Baer, M. R.; Hars, V.; Maharry, K.; Hoke, E.; Vardiman, J. W.; Bloomfield, C. D.; Larson, R. A. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood, 2010, 116 (9), 1413-1421.
125. Robak, T.; Szmigielska-Kaplon, A.; Pluta, A.; Grzybowska-Izydorczyk, O.; Wolska, A.; Czemerska, M.; Wierzbowska, A. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr. Med. Chem., 2011, 18 (5), 638-666.
126. Yang, K.; Wu, J.; Li, X. Recent advances in the research of P-glycoprotein inhibitors. Biosci. Trends, 2008, 2 (4), 137-146.
127. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets, 2006, 7 (7), 861-879.
128. Baumert, C.; Hilgeroth, A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med. Chem., 2009, 9 (4), 415-436.
129. Shepard, R. L.; Cao, J.; Starling, J. J.; Dantzig, A. H. Modulation of P-glycoprotein but not MRP1-or BCRP-mediated drug resistance by LY335979. Int. J. Cancer, 2003, 103 (1), 121-125.
130. Tang, R.; Faussat, A. M.; Perrot, J. Y.; Marjanovic, Z.; Cohen, S.; Storme, T.; Morjani, H.; Legrand, O.; Marie, J. P. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer, 2008, 8, 51.
131. Hall, M. D.; Handley, M. D.; Gottesman, M. M. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci, 2009, 30 (10), 546-56.
132. Gouaze-Andersson, V.; Cabot, M. C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta, 2006, 1758 (12), 2096-2103.
133. Cabot, M. C., Ceramide and Multidrug Resistance. In Apoptosis, Senescence, and Cancer, Second ed.; Gewirtz, D. A.; Holt, S. E.; Grant, S., Eds. Humana Press Inc: Totowa, NJ, 2007; pp 299-312.
134. Reynolds, C. P.; Maurer, B. J.; Kolesnick, R. N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett., 2004, 206 (2), 169-180.
135. Olshefski, R. S.; Ladisch, S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int. J. Cancer., 2001, 93 (1), 131-138.
136. Lavie, Y.; Cao, H.; Bursten, S. L.; Giuliano, A. E.; Cabot, M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem., 1996, 271 (32), 19530-19536.
137. Gouaze, V.; Yu, J. Y.; Bleicher, R. J.; Han, T. Y.; Liu, Y. Y.; Wang, H.; Gottesman, M. M.; Bitterman, A.; Giuliano, A. E.; Cabot, M. C. Overexpression of glucosylceramide synthase and Pglycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther., 2004, 3 (5), 633-639.
138. Bleicher, R. J.; Cabot, M. C. Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta, 2002, 1585 (2-3), 172-178.
139. Gouaze, V.; Liu, Y. Y.; Prickett, C. S.; Yu, J. Y.; Giuliano, A. E.; Cabot, M. C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res., 2005, 65 (9), 3861-3867.
140. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu Rev Med, 2002, 53, 615-27.
141. Kohno, K.; Sato, S.; Takano, H.; Matsuo, K.; Kuwano, M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun., 1989, 165 (3), 1415-1421.
142. Chaudhary, P. M.; Roninson, I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst., 1993, 85 (8), 632-639.
143. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem., 1999, 274 (2), 1140-1146.
144. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Cabot, M. C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J., 2001, 15 (3), 719-730.
145. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Hansen, N.; Cabot, M. C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem., 2000, 275 (10), 7138-7143.
146. Liu, Y. Y.; Cabot, M. C. Development of a mammalian Tet-on expression cell line: glucosylceramide synthase regulates TNFalpha-induced apoptosis. Methods Mol. Biol., 2004, 249, 177-192.
147. Liu, Y. Y.; Han, T. Y.; Giuliano, A. E.; Ichikawa, S.; Hirabayashi, Y.; Cabot, M. C. Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp. Cell Res., 1999, 252 (2), 464-470.
148. Pena, L. A.; Fuks, Z.; Kolesnick, R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem. Pharmacol., 1997, 53 (5), 615-621.
149. Di Sano, F.; Di Bartolomeo, S.; Fazi, B.; Fiorentini, C.; Matarrese, P.; Spinedi, A.; Piacentini, M. Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death Differ., 2002, 9 (6), 693-695.
150. Deng, W.; Li, R.; Guerrera, M.; Liu, Y.; Ladisch, S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology, 2002, 12 (3), 145-152.
151. Liu, Y. Y.; Han, T. Y.; Yu, J. Y.; Bitterman, A.; Le, A.; Giuliano, A. E.; Cabot, M. C. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res., 2004, 45 (5), 933-940.
152. Xie, P.; Shen, Y. F.; Shi, Y. P.; Ge, S. M.; Gu, Z. H.; Wang, J.; Mu, H. J.; Zhang, B.; Qiao, W. Z.; Xie, K. M. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk. Res., 2008, 32 (3), 475-480.
153. Grazide, S.; Terrisse, A. D.; Lerouge, S.; Laurent, G.; Jaffrezou, J. P. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines. J. Biol. Chem., 2004, 279 (18), 18256-18261.
154. Itoh, M.; Kitano, T.; Watanabe, M.; Kondo, T.; Yabu, T.; Taguchi, Y.; Iwai, K.; Tashima, M.; Uchiyama, T.; Okazaki, T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res., 2003, 9 (1), 415-423.
155. Gerrard, G.; Butters, T. D.; Ganeshaguru, K.; Mehta, A. B. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur. J. Pharmacol., 2009, 609 (1-3), 34-39.
156. Cakir, Z.; Saydam, G.; Sahin, F.; Baran, Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J. Cancer Res. Clin. Oncol., 2010, 137 (2), 279-286.
157. Baran, Y.; Salas, A.; Senkal, C. E.; Gunduz, U.; Bielawski, J.; Obeid, L. M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282 (15), 10922-10934.
158. Ricci, C.; Onida, F.; Servida, F.; Radaelli, F.; Saporiti, G.; Todoerti, K.; Deliliers, G. L.; Ghidoni, R. In vitro anti-leukaemia activity of sphingosine kinase inhibitor. Br. J. Haematol., 2009, 144 (3), 350-357.
159. Morjani, H.; Aouali, N.; Belhoussine, R.; Veldman, R. J.; Levade, T.; Manfait, M. Elevation of glucosylceramide in multidrugresistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Cancer, 2001, 94 (2), 157-165.
160. Ferrao, P.; Sincock, P.; Cole, S.; Ashman, L. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk. Res., 2001, 25 (5), 395-405.
161. Molinari, A.; Cianfriglia, M.; Meschini, S.; Calcabrini, A.; Arancia, G. P-glycoprotein expression in the Golgi apparatus of multidrugresistant cells. Int. J. Cancer., 1994, 59 (6), 789-795.
162. Munteanu, E.; Verdier, M.; Grandjean-Forestier, F.; Stenger, C.; Jayat-Vignoles, C.; Huet, S.; Robert, J.; Ratinaud, M. H. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem. Pharmacol., 2006, 71 (8), 1162-1174.
163. Chapman, J. V.; Gouaze-Andersson, V.; Cabot, M. C. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int. J. Oncol., 2010, 37 (6), 1591-1597.
164. Halter, D.; Neumann, S.; van Dijk, S. M.; Wolthoorn, J.; de Maziere, A. M.; Vieira, O. V.; Mattjus, P.; Klumperman, J.; van Meer, G.; Sprong, H. Pre-and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell. Biol., 2007, 179 (1), 101-115.
165. Molinari, A.; Calcabrini, A.; Meschini, S.; Stringaro, A.; Crateri, P.; Toccacieli, L.; Marra, M.; Colone, M.; Cianfriglia, M.; Arancia, G. Subcellular detection and localization of the drug transporter Pglycoprotein in cultured tumor cells. Curr. Protein Pept. Sci., 2002, 3 (6), 653-670.
166. Cabot, M. C.; Karimi, R.; Chapman, J. V.; Kester, M.; Shanmugavelandy, S.; Rosenberg, D. W.; Madigan, J. The effect of Pglycoprotein antagonists on short-chain ceramide cytotoxicity in cancer cells. Faseb J., 2011, 25, 739.5.
167. Chapman, J. V.; Gouaze-Andersson, V.; Karimi, R.; Messner, M. C.; Cabot, M. C. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. Exp. Cell Res., 2011, 317 (12), 1736-1745.
168. Shabbits, J. A.; Mayer, L. D. P-glycoprotein modulates ceramidemediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther., 2002, 1 (3), 205-213.
169. Turzanski, J.; Grundy, M.; Shang, S.; Russell, N.; Pallis, M. Pglycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp. Hematol., 2005, 33 (1), 62-72.
170. Lucci, A.; Cho, W. I.; Han, T. Y.; Giuliano, A. E.; Morton, D. L.; Cabot, M. C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res., 1998, 18 (1B), 475-480.
171. Lucci, A.; Han, T. Y.; Liu, Y. Y.; Giuliano, A. E.; Cabot, M. C. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int. J. Oncol., 1999, 15 (3), 541-546.
172. Lavie, Y.; Cao, H.; Volner, A.; Lucci, A.; Han, T. Y.; Geffen, V.; Giuliano, A. E.; Cabot, M. C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem., 1997, 272 (3), 1682-1687.
173. Liu, Y. Y.; Yu, J. Y.; Yin, D.; Patwardhan, G. A.; Gupta, V.; Hirabayashi, Y.; Holleran, W. M.; Giuliano, A. E.; Jazwinski, S. M.; Gouaze-Andersson, V.; Consoli, D. P.; Cabot, M. C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J., 2008, 22 (7), 2541-2551.
174. Charles, A. G.; Han, T. Y.; Liu, Y. Y.; Hansen, N.; Giuliano, A. E.; Cabot, M. C. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother. Pharmacol., 2001, 47 (5), 444-450.
175. Chai, L.; McLaren, R. P.; Byrne, A.; Chuang, W. L.; Huang, Y.; Dufault, M. R.; Pacheco, J.; Madhiwalla, S.; Zhang, X.; Zhang, M.; Teicher, B. A.; Carter, K.; Cheng, S. H.; Leonard, J. P.; Xiang, Y.; Vasconcelles, M.; Goldberg, M. A.; Copeland, D. P.; Klinger, K. W.; Lillie, J.; Madden, S. L.; Jiang, Y. A. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int. J. Oncol., 2011, 38 (3), 701-711.
176. Mandlekar, S.; Kong, A. N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 2001, 6 (6), 469-477.
177. Smyth, M. J.; Krasovskis, E.; Sutton, V. R.; Johnstone, R. W. The drug efflux protein, P-glycoprotein, additionally protects drugresistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A., 1998, 95 (12), 7024-7029.
178. Johnstone, R. W.; Cretney, E.; Smyth, M. J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspaseindependent, cell death. Blood, 1999, 93 (3), 1075-1085.
179. Bezombes, C.; Maestre, N.; Laurent, G.; Levade, T.; Bettaieb, A.; Jaffrezou, J. P. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. Faseb J., 1998, 12 (1), 101-109.
180. Plo, I.; Lehne, G.; Beckstrom, K. J.; Maestre, N.; Bettaieb, A.; Laurent, G.; Lautier, D. Influence of ceramide metabolism on Pglycoprotein function in immature acute myeloid leukemia KG1a cells. Mo.l Pharmacol., 2002, 62 (2), 304-312.
181. Liu, Y. Y.; Gupta, V.; Patwardhan, G. A.; Bhinge, K.; Zhao, Y.; Bao, J.; Mehendale, H.; Cabot, M. C.; Li, Y. T.; Jazwinski, S. M. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer, 2010, 9, 145.
182. Zolnik, B. S.; Stern, S. T.; Kaiser, J. M.; Heakal, Y.; Clogston, J. D.; Kester, M.; McNeil, S. E. Rapid distribution of liposomal shortchain ceramide in vitro and in vivo. Drug Metab. Dispos., 2008, 36 (8), 1709-1715.
183. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S. F.; Kaiser, J.; Shanmugavelandy, S. S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K. T.; Jarbadan, N. R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T. J.; Kester, M.; Loughran, T. P., Jr. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116 (20), 4192-4201.